Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.94
+0.30008.24%
Post-market: 3.940.00000.00%19:30 EDT
Volume:156.51K
Turnover:603.88K
Market Cap:397.94M
PE:-9.16
High:3.97
Open:3.64
Low:3.64
Close:3.64
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:0.64
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-2.86
PE(LYR):-8.13

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Boundless Bio, Galectin, UniQure

Reuters
·
Jun 23

BUZZ-Galectin Therapeutics rises as FDA clears path for late-stage liver drug study

Reuters
·
Jun 23

Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial

MT Newswires Live
·
Jun 23

Galectin Therapeutics reaches alignment with FDA on belapectin pathway

TIPRANKS
·
Jun 23

Galectin Therapeutics - to Evaluate Single 2 Mg Dose of Belapectin in Phase 3 Trial

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics - FDA Accepts Galectin's Blinded Central Endoscopy Review Process

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics - to File Phase 3 Protocol for Belapectin in Q3 2026 - SEC Filing

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics: Positive Type C Meeting With FDA for Belapectin in Patients With Mash Cirrhosis and Portal Hypertension

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics - Reaches Agreement With FDA on Primary Endpoint and Regulatory Path for Potential Full Approval of Belapectin

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension

Reuters
·
Jun 23

Galectin Therapeutics CMO Jamil Khurram sells 568 common shares for $1,761.43

Reuters
·
May 28

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 28

Galectin Therapeutics presents belapectin data at EASL 2026

TIPRANKS
·
May 27

Galectin says belapectin cuts new varices in NAVIGATE MASH cirrhosis trial analysis

Reuters
·
May 27

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

GlobeNewswire
·
May 27

H.C. Wainwright Keeps Their Buy Rating on Galectin Therapeutics (GALT)

TIPRANKS
·
May 22

Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)

TIPRANKS
·
May 16

Galectin Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate

Benzinga Earnings
·
May 15

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 15